Comment
doi: 10.1128/AAC.01705-12.
Contradictory results with high-dosage rifamycin in mice and humans
- PMID: 23341429
- PMCID: PMC3553725
- DOI: 10.1128/AAC.01705-12
Item in Clipboard
Comment
Contradictory results with high-dosage rifamycin in mice and humans
Antimicrob Agents Chemother.
2013 Feb.
No abstract available
Comment in
-
Reply to "Contradictory results with high-dosage rifamycin in mice and humans".Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. Antimicrob Agents Chemother. 2013. PMID: 23341430 Free PMC article. No abstract available.
Comment on
-
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4. Antimicrob Agents Chemother. 2012. PMID: 22664964 Free PMC article.
Similar articles
-
Reply to "Contradictory results with high-dosage rifamycin in mice and humans".Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. Antimicrob Agents Chemother. 2013. PMID: 23341430 Free PMC article. No abstract available.
-
Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?Am J Respir Crit Care Med. 2005 Jul 1;172(1):4-5. doi: 10.1164/rccm.2504002. Am J Respir Crit Care Med. 2005. PMID: 15980108 No abstract available.
-
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.Lancet. 1999 May 29;353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8. Lancet. 1999. PMID: 10359410 Clinical Trial.
-
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Expert Rev Clin Pharmacol. 2017. PMID: 28803492 Review.
-
Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease.Soc Appl Bacteriol Symp Ser. 1996;25:72S-80S. Soc Appl Bacteriol Symp Ser. 1996. PMID: 8972122 Review. No abstract available.
Cited by
-
Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.PLoS Comput Biol. 2017 Jan 6;13(1):e1005321. doi: 10.1371/journal.pcbi.1005321. eCollection 2017 Jan. PLoS Comput Biol. 2017. PMID: 28060813 Free PMC article.
-
Phenotypically Adapted Mycobacterium tuberculosis Populations from Sputum Are Tolerant to First-Line Drugs.Antimicrob Agents Chemother. 2016 Mar 25;60(4):2476-83. doi: 10.1128/AAC.01380-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26883695 Free PMC article.
-
Reply to "Contradictory results with high-dosage rifamycin in mice and humans".Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. Antimicrob Agents Chemother. 2013. PMID: 23341430 Free PMC article. No abstract available.
-
High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo.Front Microbiol. 2015 Jun 23;6:641. doi: 10.3389/fmicb.2015.00641. eCollection 2015. Front Microbiol. 2015. PMID: 26157437 Free PMC article.
-
Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.Pediatr Infect Dis J. 2018 Jan;37(1):43-51. doi: 10.1097/INF.0000000000001687. Pediatr Infect Dis J. 2018. PMID: 28719501 Free PMC article.
References
-
- Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset J, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344 doi:10.1371/journal.pmed.0040344 - DOI - PMC - PubMed
-
- Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. J. Infect. Dis. 206:1030–1040 - PubMed
-
- Mitchison DA. 2012. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int. J. Tuberc. Lung Dis. 16:1186–1189 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
